Total Funding
17
38
Total FundingVenture - Series Unknown raised
Growth Score 17 in past quarter
-6 pts
Heat Score 38 in past quarter
-6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
127197
Apex Therapeutics develops and commercializes pharmaceuticals for the treatment of cancer and ocular diseases.
- Jan Elkins: Director of Clinical Operations
- Mark R. Kelley: Chief Scientific Officer & FounderPast Role: Indiana University School of Medicine, Associate Director, Wells Center for Pediatric Research
About the Company
Apex Therapeutics is an emerging clinical-stage biotechnology company founded on the scientific discoveries of Dr. Mark R. Kelley, whose groundbreaking work on APE1/Ref-1 redox protein signaling at the Indiana University School of Medicine has provided a unique insight into this novel biological target.
It was founded in 2005 and
headquartered in Indianapolis, Indiana.